nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—CYP3A4—Rosuvastatin—atherosclerosis	0.0999	0.211	CbGbCtD
Dantrolene—CYP3A4—Ezetimibe—atherosclerosis	0.0999	0.211	CbGbCtD
Dantrolene—CYP3A4—Simvastatin—atherosclerosis	0.0929	0.196	CbGbCtD
Dantrolene—CYP3A4—Pravastatin—atherosclerosis	0.0909	0.192	CbGbCtD
Dantrolene—CYP3A4—Lovastatin—atherosclerosis	0.0909	0.192	CbGbCtD
Dantrolene—RYR3—Stimuli-sensing channels—TRPV1—atherosclerosis	0.00736	0.0607	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—GJA4—atherosclerosis	0.00629	0.052	CbGpPWpGaD
Dantrolene—RYR1—Stimuli-sensing channels—TRPV1—atherosclerosis	0.00542	0.0448	CbGpPWpGaD
Dantrolene—Hepatotoxicity—Niacin—atherosclerosis	0.00527	0.013	CcSEcCtD
Dantrolene—Necrosis—Niacin—atherosclerosis	0.00518	0.0128	CcSEcCtD
Dantrolene—CYP3A4—Irinotecan Pathway—NPC1—atherosclerosis	0.00514	0.0424	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—TRPV1—atherosclerosis	0.0048	0.0396	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—GJA4—atherosclerosis	0.00464	0.0383	CbGpPWpGaD
Dantrolene—Hepatic failure—Rosuvastatin—atherosclerosis	0.00451	0.0112	CcSEcCtD
Dantrolene—Nocturia—Pravastatin—atherosclerosis	0.00432	0.0107	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—LPL—atherosclerosis	0.00384	0.0317	CbGpPWpGaD
Dantrolene—Hepatic failure—Lovastatin—atherosclerosis	0.00383	0.00946	CcSEcCtD
Dantrolene—Hepatic failure—Ezetimibe—atherosclerosis	0.00375	0.00928	CcSEcCtD
Dantrolene—Swelling—Simvastatin—atherosclerosis	0.00365	0.00901	CcSEcCtD
Dantrolene—Hepatic failure—Simvastatin—atherosclerosis	0.00358	0.00885	CcSEcCtD
Dantrolene—Muscular weakness—Rosuvastatin—atherosclerosis	0.00358	0.00885	CcSEcCtD
Dantrolene—RYR1—Ion channel transport—TRPV1—atherosclerosis	0.00354	0.0292	CbGpPWpGaD
Dantrolene—CYP3A4—Liver X Receptor Pathway—ABCG8—atherosclerosis	0.00353	0.0292	CbGpPWpGaD
Dantrolene—Pain in extremity—Lovastatin—atherosclerosis	0.00344	0.0085	CcSEcCtD
Dantrolene—Pain in extremity—Ezetimibe—atherosclerosis	0.00337	0.00834	CcSEcCtD
Dantrolene—Hepatic failure—Pravastatin—atherosclerosis	0.00324	0.008	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—APOE—atherosclerosis	0.00322	0.0266	CbGpPWpGaD
Dantrolene—Depression—Rosuvastatin—atherosclerosis	0.00312	0.00771	CcSEcCtD
Dantrolene—Haematuria—Rosuvastatin—atherosclerosis	0.00298	0.00737	CcSEcCtD
Dantrolene—Muscular weakness—Ezetimibe—atherosclerosis	0.00297	0.00735	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Niacin—atherosclerosis	0.00295	0.0073	CcSEcCtD
Dantrolene—Eosinophilia—Lovastatin—atherosclerosis	0.00294	0.00727	CcSEcCtD
Dantrolene—Diplopia—Pravastatin—atherosclerosis	0.00291	0.00719	CcSEcCtD
Dantrolene—Eosinophilia—Ezetimibe—atherosclerosis	0.00289	0.00713	CcSEcCtD
Dantrolene—Muscular weakness—Simvastatin—atherosclerosis	0.00284	0.00701	CcSEcCtD
Dantrolene—Urinary retention—Niacin—atherosclerosis	0.00281	0.00694	CcSEcCtD
Dantrolene—Hepatitis—Rosuvastatin—atherosclerosis	0.00281	0.00694	CcSEcCtD
Dantrolene—Eosinophilia—Simvastatin—atherosclerosis	0.00275	0.0068	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCG4—atherosclerosis	0.0027	0.0223	CbGpPWpGaD
Dantrolene—Muscular weakness—Niacin—atherosclerosis	0.0026	0.00644	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCG8—atherosclerosis	0.00259	0.0214	CbGpPWpGaD
Dantrolene—Muscular weakness—Pravastatin—atherosclerosis	0.00256	0.00634	CcSEcCtD
Dantrolene—Dysphagia—Niacin—atherosclerosis	0.00255	0.00631	CcSEcCtD
Dantrolene—CYP3A4—Liver X Receptor Pathway—CYP7A1—atherosclerosis	0.00253	0.0209	CbGpPWpGaD
Dantrolene—Eosinophilia—Pravastatin—atherosclerosis	0.00249	0.00615	CcSEcCtD
Dantrolene—Depression—Simvastatin—atherosclerosis	0.00247	0.00611	CcSEcCtD
Dantrolene—Hepatitis—Lovastatin—atherosclerosis	0.00238	0.00588	CcSEcCtD
Dantrolene—Hepatitis—Ezetimibe—atherosclerosis	0.00233	0.00577	CcSEcCtD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—PRKCG—atherosclerosis	0.00225	0.0186	CbGpPWpGaD
Dantrolene—Depression—Pravastatin—atherosclerosis	0.00223	0.00552	CcSEcCtD
Dantrolene—Hepatitis—Simvastatin—atherosclerosis	0.00222	0.0055	CcSEcCtD
Dantrolene—Flushing—Lovastatin—atherosclerosis	0.00221	0.00546	CcSEcCtD
Dantrolene—CYP3A4—Liver X Receptor Pathway—ABCG5—atherosclerosis	0.00219	0.0181	CbGpPWpGaD
Dantrolene—Sweating—Niacin—atherosclerosis	0.00218	0.00539	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—PRKCG—atherosclerosis	0.00218	0.018	CbGpPWpGaD
Dantrolene—Flushing—Ezetimibe—atherosclerosis	0.00216	0.00535	CcSEcCtD
Dantrolene—Chills—Lovastatin—atherosclerosis	0.00213	0.00528	CcSEcCtD
Dantrolene—Myalgia—Rosuvastatin—atherosclerosis	0.00208	0.00514	CcSEcCtD
Dantrolene—Flushing—Simvastatin—atherosclerosis	0.00206	0.0051	CcSEcCtD
Dantrolene—Haemoglobin—Niacin—atherosclerosis	0.00205	0.00508	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—IL1B—atherosclerosis	0.00205	0.017	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCG1—atherosclerosis	0.00205	0.0169	CbGpPWpGaD
Dantrolene—Hepatitis—Niacin—atherosclerosis	0.00204	0.00505	CcSEcCtD
Dantrolene—Haemorrhage—Niacin—atherosclerosis	0.00204	0.00505	CcSEcCtD
Dantrolene—Erythema—Ezetimibe—atherosclerosis	0.00203	0.00502	CcSEcCtD
Dantrolene—Dysgeusia—Lovastatin—atherosclerosis	0.00203	0.00501	CcSEcCtD
Dantrolene—Hepatitis—Pravastatin—atherosclerosis	0.00201	0.00497	CcSEcCtD
Dantrolene—Confusional state—Rosuvastatin—atherosclerosis	0.00201	0.00497	CcSEcCtD
Dantrolene—Back pain—Lovastatin—atherosclerosis	0.002	0.00495	CcSEcCtD
Dantrolene—Chills—Simvastatin—atherosclerosis	0.002	0.00493	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCG4—atherosclerosis	0.00199	0.0165	CbGpPWpGaD
Dantrolene—Visual impairment—Niacin—atherosclerosis	0.00197	0.00487	CcSEcCtD
Dantrolene—Back pain—Ezetimibe—atherosclerosis	0.00196	0.00486	CcSEcCtD
Dantrolene—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00195	0.00483	CcSEcCtD
Dantrolene—Vision blurred—Lovastatin—atherosclerosis	0.00195	0.00482	CcSEcCtD
Dantrolene—Visual impairment—Pravastatin—atherosclerosis	0.00194	0.00479	CcSEcCtD
Dantrolene—Erythema—Simvastatin—atherosclerosis	0.00194	0.00479	CcSEcCtD
Dantrolene—Ill-defined disorder—Lovastatin—atherosclerosis	0.00192	0.00475	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCG8—atherosclerosis	0.00191	0.0158	CbGpPWpGaD
Dantrolene—Dysgeusia—Simvastatin—atherosclerosis	0.0019	0.00469	CcSEcCtD
Dantrolene—Flushing—Niacin—atherosclerosis	0.0019	0.00469	CcSEcCtD
Dantrolene—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00188	0.00466	CcSEcCtD
Dantrolene—Anaemia—Ezetimibe—atherosclerosis	0.00188	0.00464	CcSEcCtD
Dantrolene—Malaise—Lovastatin—atherosclerosis	0.00187	0.00462	CcSEcCtD
Dantrolene—Flushing—Pravastatin—atherosclerosis	0.00187	0.00461	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—CYP7A1—atherosclerosis	0.00186	0.0153	CbGpPWpGaD
Dantrolene—Leukopenia—Lovastatin—atherosclerosis	0.00185	0.00458	CcSEcCtD
Dantrolene—Chills—Niacin—atherosclerosis	0.00183	0.00453	CcSEcCtD
Dantrolene—Malaise—Ezetimibe—atherosclerosis	0.00183	0.00453	CcSEcCtD
Dantrolene—Vision blurred—Simvastatin—atherosclerosis	0.00183	0.00451	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00182	0.00449	CcSEcCtD
Dantrolene—Chills—Pravastatin—atherosclerosis	0.0018	0.00446	CcSEcCtD
Dantrolene—Insomnia—Rosuvastatin—atherosclerosis	0.0018	0.00446	CcSEcCtD
Dantrolene—Ill-defined disorder—Simvastatin—atherosclerosis	0.0018	0.00444	CcSEcCtD
Dantrolene—Anaemia—Simvastatin—atherosclerosis	0.00179	0.00443	CcSEcCtD
Dantrolene—Erythema—Niacin—atherosclerosis	0.00178	0.0044	CcSEcCtD
Dantrolene—Myalgia—Lovastatin—atherosclerosis	0.00176	0.00436	CcSEcCtD
Dantrolene—Dyspepsia—Rosuvastatin—atherosclerosis	0.00176	0.00434	CcSEcCtD
Dantrolene—Hypertension—Ezetimibe—atherosclerosis	0.00175	0.00433	CcSEcCtD
Dantrolene—Malaise—Simvastatin—atherosclerosis	0.00175	0.00432	CcSEcCtD
Dantrolene—Tension—Niacin—atherosclerosis	0.00174	0.00431	CcSEcCtD
Dantrolene—Discomfort—Lovastatin—atherosclerosis	0.00174	0.00431	CcSEcCtD
Dantrolene—Leukopenia—Simvastatin—atherosclerosis	0.00173	0.00429	CcSEcCtD
Dantrolene—Myalgia—Ezetimibe—atherosclerosis	0.00173	0.00427	CcSEcCtD
Dantrolene—Nervousness—Niacin—atherosclerosis	0.00173	0.00427	CcSEcCtD
Dantrolene—Dry mouth—Lovastatin—atherosclerosis	0.00172	0.00426	CcSEcCtD
Dantrolene—Tension—Pravastatin—atherosclerosis	0.00172	0.00425	CcSEcCtD
Dantrolene—Dysgeusia—Pravastatin—atherosclerosis	0.00171	0.00424	CcSEcCtD
Dantrolene—Discomfort—Ezetimibe—atherosclerosis	0.00171	0.00422	CcSEcCtD
Dantrolene—Constipation—Rosuvastatin—atherosclerosis	0.00171	0.00422	CcSEcCtD
Dantrolene—Pain—Rosuvastatin—atherosclerosis	0.00171	0.00422	CcSEcCtD
Dantrolene—Confusional state—Lovastatin—atherosclerosis	0.0017	0.00421	CcSEcCtD
Dantrolene—Nervousness—Pravastatin—atherosclerosis	0.0017	0.0042	CcSEcCtD
Dantrolene—Dry mouth—Ezetimibe—atherosclerosis	0.00169	0.00418	CcSEcCtD
Dantrolene—Anaphylactic shock—Lovastatin—atherosclerosis	0.00169	0.00418	CcSEcCtD
Dantrolene—Vision blurred—Niacin—atherosclerosis	0.00168	0.00414	CcSEcCtD
Dantrolene—Confusional state—Ezetimibe—atherosclerosis	0.00167	0.00413	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—TRPV1—atherosclerosis	0.00167	0.0138	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—PRKCG—atherosclerosis	0.00166	0.0137	CbGpPWpGaD
Dantrolene—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00166	0.0041	CcSEcCtD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—CYP7A1—atherosclerosis	0.00166	0.0137	CbGpPWpGaD
Dantrolene—Thrombocytopenia—Lovastatin—atherosclerosis	0.00165	0.00409	CcSEcCtD
Dantrolene—Vision blurred—Pravastatin—atherosclerosis	0.00165	0.00408	CcSEcCtD
Dantrolene—Myalgia—Simvastatin—atherosclerosis	0.00165	0.00408	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—MAPK3—atherosclerosis	0.00164	0.0136	CbGpPWpGaD
Dantrolene—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00164	0.00406	CcSEcCtD
Dantrolene—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00163	0.00403	CcSEcCtD
Dantrolene—Discomfort—Simvastatin—atherosclerosis	0.00163	0.00403	CcSEcCtD
Dantrolene—Ill-defined disorder—Pravastatin—atherosclerosis	0.00162	0.00402	CcSEcCtD
Dantrolene—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00162	0.00401	CcSEcCtD
Dantrolene—Anaemia—Pravastatin—atherosclerosis	0.00162	0.004	CcSEcCtD
Dantrolene—Anorexia—Lovastatin—atherosclerosis	0.00161	0.00398	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCG5—atherosclerosis	0.00161	0.0133	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—PRKCG—atherosclerosis	0.00161	0.0133	CbGpPWpGaD
Dantrolene—Confusional state—Simvastatin—atherosclerosis	0.00159	0.00394	CcSEcCtD
Dantrolene—Leukopenia—Niacin—atherosclerosis	0.00159	0.00394	CcSEcCtD
Dantrolene—Urticaria—Rosuvastatin—atherosclerosis	0.00158	0.00392	CcSEcCtD
Dantrolene—Anaphylactic shock—Simvastatin—atherosclerosis	0.00158	0.00391	CcSEcCtD
Dantrolene—Malaise—Pravastatin—atherosclerosis	0.00158	0.0039	CcSEcCtD
Dantrolene—Abdominal pain—Rosuvastatin—atherosclerosis	0.00158	0.0039	CcSEcCtD
Dantrolene—Leukopenia—Pravastatin—atherosclerosis	0.00157	0.00387	CcSEcCtD
Dantrolene—Thrombocytopenia—Simvastatin—atherosclerosis	0.00155	0.00383	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00154	0.00381	CcSEcCtD
Dantrolene—Insomnia—Lovastatin—atherosclerosis	0.00153	0.00378	CcSEcCtD
Dantrolene—CYP3A4—Farnesoid X Receptor  Pathway—CYP7A1—atherosclerosis	0.00151	0.0125	CbGpPWpGaD
Dantrolene—Myalgia—Niacin—atherosclerosis	0.00151	0.00374	CcSEcCtD
Dantrolene—Hypertension—Pravastatin—atherosclerosis	0.00151	0.00374	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCG1—atherosclerosis	0.00151	0.0125	CbGpPWpGaD
Dantrolene—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00151	0.00373	CcSEcCtD
Dantrolene—Anorexia—Simvastatin—atherosclerosis	0.00151	0.00372	CcSEcCtD
Dantrolene—Insomnia—Ezetimibe—atherosclerosis	0.0015	0.00371	CcSEcCtD
Dantrolene—Myalgia—Pravastatin—atherosclerosis	0.00149	0.00368	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—TNF—atherosclerosis	0.00149	0.0123	CbGpPWpGaD
Dantrolene—Dyspepsia—Lovastatin—atherosclerosis	0.00149	0.00368	CcSEcCtD
Dantrolene—Dry mouth—Niacin—atherosclerosis	0.00148	0.00366	CcSEcCtD
Dantrolene—Discomfort—Pravastatin—atherosclerosis	0.00147	0.00364	CcSEcCtD
Dantrolene—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00147	0.00363	CcSEcCtD
Dantrolene—Decreased appetite—Lovastatin—atherosclerosis	0.00147	0.00363	CcSEcCtD
Dantrolene—Dyspepsia—Ezetimibe—atherosclerosis	0.00146	0.00361	CcSEcCtD
Dantrolene—Fatigue—Lovastatin—atherosclerosis	0.00146	0.0036	CcSEcCtD
Dantrolene—Anaphylactic shock—Niacin—atherosclerosis	0.00145	0.00359	CcSEcCtD
Dantrolene—Pain—Lovastatin—atherosclerosis	0.00144	0.00357	CcSEcCtD
Dantrolene—Constipation—Lovastatin—atherosclerosis	0.00144	0.00357	CcSEcCtD
Dantrolene—Confusional state—Pravastatin—atherosclerosis	0.00144	0.00356	CcSEcCtD
Dantrolene—Decreased appetite—Ezetimibe—atherosclerosis	0.00144	0.00356	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00144	0.00356	CcSEcCtD
Dantrolene—Asthenia—Rosuvastatin—atherosclerosis	0.00143	0.00354	CcSEcCtD
Dantrolene—Insomnia—Simvastatin—atherosclerosis	0.00143	0.00353	CcSEcCtD
Dantrolene—Anaphylactic shock—Pravastatin—atherosclerosis	0.00143	0.00353	CcSEcCtD
Dantrolene—Fatigue—Ezetimibe—atherosclerosis	0.00143	0.00353	CcSEcCtD
Dantrolene—Pain—Ezetimibe—atherosclerosis	0.00142	0.0035	CcSEcCtD
Dantrolene—Constipation—Ezetimibe—atherosclerosis	0.00142	0.0035	CcSEcCtD
Dantrolene—Tachycardia—Niacin—atherosclerosis	0.00142	0.0035	CcSEcCtD
Dantrolene—Pruritus—Rosuvastatin—atherosclerosis	0.00141	0.00349	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—NOS3—atherosclerosis	0.00141	0.0116	CbGpPWpGaD
Dantrolene—Hyperhidrosis—Niacin—atherosclerosis	0.0014	0.00347	CcSEcCtD
Dantrolene—Thrombocytopenia—Pravastatin—atherosclerosis	0.0014	0.00346	CcSEcCtD
Dantrolene—Feeling abnormal—Lovastatin—atherosclerosis	0.00139	0.00344	CcSEcCtD
Dantrolene—Dyspepsia—Simvastatin—atherosclerosis	0.00139	0.00344	CcSEcCtD
Dantrolene—CYP3A4—Aflatoxin B1 metabolism—GSTM1—atherosclerosis	0.00139	0.0115	CbGpPWpGaD
Dantrolene—Anorexia—Niacin—atherosclerosis	0.00138	0.00342	CcSEcCtD
Dantrolene—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00138	0.00342	CcSEcCtD
Dantrolene—Hyperhidrosis—Pravastatin—atherosclerosis	0.00138	0.00342	CcSEcCtD
Dantrolene—Decreased appetite—Simvastatin—atherosclerosis	0.00137	0.0034	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—CYP7A1—atherosclerosis	0.00137	0.0113	CbGpPWpGaD
Dantrolene—Feeling abnormal—Ezetimibe—atherosclerosis	0.00137	0.00338	CcSEcCtD
Dantrolene—Diarrhoea—Rosuvastatin—atherosclerosis	0.00136	0.00337	CcSEcCtD
Dantrolene—Fatigue—Simvastatin—atherosclerosis	0.00136	0.00337	CcSEcCtD
Dantrolene—Anorexia—Pravastatin—atherosclerosis	0.00136	0.00337	CcSEcCtD
Dantrolene—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00136	0.00335	CcSEcCtD
Dantrolene—Pain—Simvastatin—atherosclerosis	0.00135	0.00334	CcSEcCtD
Dantrolene—Constipation—Simvastatin—atherosclerosis	0.00135	0.00334	CcSEcCtD
Dantrolene—Urticaria—Lovastatin—atherosclerosis	0.00134	0.00332	CcSEcCtD
Dantrolene—Abdominal pain—Lovastatin—atherosclerosis	0.00134	0.0033	CcSEcCtD
Dantrolene—Body temperature increased—Lovastatin—atherosclerosis	0.00134	0.0033	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00132	0.00327	CcSEcCtD
Dantrolene—Dizziness—Rosuvastatin—atherosclerosis	0.00132	0.00326	CcSEcCtD
Dantrolene—Urticaria—Ezetimibe—atherosclerosis	0.00132	0.00325	CcSEcCtD
Dantrolene—Insomnia—Niacin—atherosclerosis	0.00131	0.00324	CcSEcCtD
Dantrolene—Abdominal pain—Ezetimibe—atherosclerosis	0.00131	0.00324	CcSEcCtD
Dantrolene—Body temperature increased—Ezetimibe—atherosclerosis	0.00131	0.00324	CcSEcCtD
Dantrolene—Feeling abnormal—Simvastatin—atherosclerosis	0.0013	0.00322	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.0013	0.00322	CcSEcCtD
Dantrolene—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00129	0.0032	CcSEcCtD
Dantrolene—Insomnia—Pravastatin—atherosclerosis	0.00129	0.0032	CcSEcCtD
Dantrolene—Somnolence—Niacin—atherosclerosis	0.00129	0.00319	CcSEcCtD
Dantrolene—Dyspepsia—Niacin—atherosclerosis	0.00128	0.00316	CcSEcCtD
Dantrolene—Decreased appetite—Niacin—atherosclerosis	0.00126	0.00312	CcSEcCtD
Dantrolene—Dyspepsia—Pravastatin—atherosclerosis	0.00126	0.00311	CcSEcCtD
Dantrolene—Rash—Rosuvastatin—atherosclerosis	0.00126	0.00311	CcSEcCtD
Dantrolene—Dermatitis—Rosuvastatin—atherosclerosis	0.00126	0.00311	CcSEcCtD
Dantrolene—Urticaria—Simvastatin—atherosclerosis	0.00126	0.0031	CcSEcCtD
Dantrolene—Abdominal pain—Simvastatin—atherosclerosis	0.00125	0.00309	CcSEcCtD
Dantrolene—Body temperature increased—Simvastatin—atherosclerosis	0.00125	0.00309	CcSEcCtD
Dantrolene—Headache—Rosuvastatin—atherosclerosis	0.00125	0.00309	CcSEcCtD
Dantrolene—Hypersensitivity—Lovastatin—atherosclerosis	0.00124	0.00308	CcSEcCtD
Dantrolene—Decreased appetite—Pravastatin—atherosclerosis	0.00124	0.00307	CcSEcCtD
Dantrolene—Pain—Niacin—atherosclerosis	0.00124	0.00307	CcSEcCtD
Dantrolene—Fatigue—Pravastatin—atherosclerosis	0.00123	0.00305	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—TRPV1—atherosclerosis	0.00123	0.0102	CbGpPWpGaD
Dantrolene—Pain—Pravastatin—atherosclerosis	0.00122	0.00302	CcSEcCtD
Dantrolene—Constipation—Pravastatin—atherosclerosis	0.00122	0.00302	CcSEcCtD
Dantrolene—Hypersensitivity—Ezetimibe—atherosclerosis	0.00122	0.00302	CcSEcCtD
Dantrolene—Asthenia—Lovastatin—atherosclerosis	0.00121	0.003	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL1B—atherosclerosis	0.0012	0.00989	CbGpPWpGaD
Dantrolene—Pruritus—Lovastatin—atherosclerosis	0.0012	0.00296	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—CETP—atherosclerosis	0.00119	0.00983	CbGpPWpGaD
Dantrolene—Asthenia—Ezetimibe—atherosclerosis	0.00119	0.00294	CcSEcCtD
Dantrolene—Gastrointestinal pain—Niacin—atherosclerosis	0.00119	0.00293	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCG5—atherosclerosis	0.00119	0.00979	CbGpPWpGaD
Dantrolene—Nausea—Rosuvastatin—atherosclerosis	0.00118	0.00293	CcSEcCtD
Dantrolene—Feeling abnormal—Pravastatin—atherosclerosis	0.00118	0.00291	CcSEcCtD
Dantrolene—Pruritus—Ezetimibe—atherosclerosis	0.00117	0.0029	CcSEcCtD
Dantrolene—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00117	0.00289	CcSEcCtD
Dantrolene—Hypersensitivity—Simvastatin—atherosclerosis	0.00116	0.00288	CcSEcCtD
Dantrolene—Diarrhoea—Lovastatin—atherosclerosis	0.00116	0.00286	CcSEcCtD
Dantrolene—Urticaria—Niacin—atherosclerosis	0.00115	0.00285	CcSEcCtD
Dantrolene—Abdominal pain—Niacin—atherosclerosis	0.00115	0.00284	CcSEcCtD
Dantrolene—Body temperature increased—Niacin—atherosclerosis	0.00115	0.00284	CcSEcCtD
Dantrolene—Urticaria—Pravastatin—atherosclerosis	0.00114	0.00281	CcSEcCtD
Dantrolene—Asthenia—Simvastatin—atherosclerosis	0.00113	0.0028	CcSEcCtD
Dantrolene—Diarrhoea—Ezetimibe—atherosclerosis	0.00113	0.0028	CcSEcCtD
Dantrolene—Body temperature increased—Pravastatin—atherosclerosis	0.00113	0.00279	CcSEcCtD
Dantrolene—Abdominal pain—Pravastatin—atherosclerosis	0.00113	0.00279	CcSEcCtD
Dantrolene—Pruritus—Simvastatin—atherosclerosis	0.00112	0.00276	CcSEcCtD
Dantrolene—Dizziness—Lovastatin—atherosclerosis	0.00112	0.00276	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—NFKB1—atherosclerosis	0.00112	0.00922	CbGpPWpGaD
Dantrolene—Dizziness—Ezetimibe—atherosclerosis	0.0011	0.00271	CcSEcCtD
Dantrolene—Diarrhoea—Simvastatin—atherosclerosis	0.00108	0.00267	CcSEcCtD
Dantrolene—Vomiting—Lovastatin—atherosclerosis	0.00107	0.00266	CcSEcCtD
Dantrolene—Hypersensitivity—Niacin—atherosclerosis	0.00107	0.00264	CcSEcCtD
Dantrolene—Rash—Lovastatin—atherosclerosis	0.00107	0.00263	CcSEcCtD
Dantrolene—Dermatitis—Lovastatin—atherosclerosis	0.00106	0.00263	CcSEcCtD
Dantrolene—Headache—Lovastatin—atherosclerosis	0.00106	0.00262	CcSEcCtD
Dantrolene—Vomiting—Ezetimibe—atherosclerosis	0.00105	0.00261	CcSEcCtD
Dantrolene—Hypersensitivity—Pravastatin—atherosclerosis	0.00105	0.0026	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—PLAT—atherosclerosis	0.00105	0.00866	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG1—atherosclerosis	0.00105	0.00866	CbGpPWpGaD
Dantrolene—Dizziness—Simvastatin—atherosclerosis	0.00105	0.00258	CcSEcCtD
Dantrolene—Rash—Ezetimibe—atherosclerosis	0.00104	0.00258	CcSEcCtD
Dantrolene—Dermatitis—Ezetimibe—atherosclerosis	0.00104	0.00258	CcSEcCtD
Dantrolene—Asthenia—Niacin—atherosclerosis	0.00104	0.00257	CcSEcCtD
Dantrolene—Headache—Ezetimibe—atherosclerosis	0.00104	0.00257	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—NOS3—atherosclerosis	0.00104	0.00857	CbGpPWpGaD
Dantrolene—Pruritus—Niacin—atherosclerosis	0.00103	0.00254	CcSEcCtD
Dantrolene—Asthenia—Pravastatin—atherosclerosis	0.00103	0.00253	CcSEcCtD
Dantrolene—Pruritus—Pravastatin—atherosclerosis	0.00101	0.0025	CcSEcCtD
Dantrolene—Vomiting—Simvastatin—atherosclerosis	0.001	0.00248	CcSEcCtD
Dantrolene—Nausea—Lovastatin—atherosclerosis	0.001	0.00248	CcSEcCtD
Dantrolene—Rash—Simvastatin—atherosclerosis	0.000997	0.00246	CcSEcCtD
Dantrolene—Dermatitis—Simvastatin—atherosclerosis	0.000996	0.00246	CcSEcCtD
Dantrolene—Diarrhoea—Niacin—atherosclerosis	0.000993	0.00245	CcSEcCtD
Dantrolene—Headache—Simvastatin—atherosclerosis	0.00099	0.00245	CcSEcCtD
Dantrolene—Nausea—Ezetimibe—atherosclerosis	0.000984	0.00243	CcSEcCtD
Dantrolene—Diarrhoea—Pravastatin—atherosclerosis	0.000978	0.00242	CcSEcCtD
Dantrolene—Dizziness—Niacin—atherosclerosis	0.00096	0.00237	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP7A1—atherosclerosis	0.000951	0.00785	CbGpPWpGaD
Dantrolene—Dizziness—Pravastatin—atherosclerosis	0.000945	0.00234	CcSEcCtD
Dantrolene—Nausea—Simvastatin—atherosclerosis	0.000939	0.00232	CcSEcCtD
Dantrolene—Vomiting—Niacin—atherosclerosis	0.000923	0.00228	CcSEcCtD
Dantrolene—Rash—Niacin—atherosclerosis	0.000915	0.00226	CcSEcCtD
Dantrolene—Dermatitis—Niacin—atherosclerosis	0.000914	0.00226	CcSEcCtD
Dantrolene—Headache—Niacin—atherosclerosis	0.000909	0.00225	CcSEcCtD
Dantrolene—Vomiting—Pravastatin—atherosclerosis	0.000909	0.00225	CcSEcCtD
Dantrolene—Rash—Pravastatin—atherosclerosis	0.000901	0.00223	CcSEcCtD
Dantrolene—Dermatitis—Pravastatin—atherosclerosis	0.0009	0.00223	CcSEcCtD
Dantrolene—Headache—Pravastatin—atherosclerosis	0.000895	0.00221	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—PLG—atherosclerosis	0.000892	0.00736	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL1B—atherosclerosis	0.000883	0.00729	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—CETP—atherosclerosis	0.000877	0.00724	CbGpPWpGaD
Dantrolene—Nausea—Niacin—atherosclerosis	0.000862	0.00213	CcSEcCtD
Dantrolene—Nausea—Pravastatin—atherosclerosis	0.000849	0.0021	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—NFKB1—atherosclerosis	0.000823	0.0068	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—HMOX1—atherosclerosis	0.000823	0.0068	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—atherosclerosis	0.000823	0.00679	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—APOB—atherosclerosis	0.000788	0.00651	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—PLAT—atherosclerosis	0.000773	0.00639	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL6—atherosclerosis	0.000701	0.00579	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—PPARA—atherosclerosis	0.000665	0.00549	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—PLG—atherosclerosis	0.000658	0.00543	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—GSTM1—atherosclerosis	0.000653	0.00539	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—APOA1—atherosclerosis	0.000624	0.00515	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	0.000607	0.00501	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7A1—atherosclerosis	0.000604	0.00498	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP7A1—atherosclerosis	0.000596	0.00492	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—APOB—atherosclerosis	0.000581	0.0048	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—atherosclerosis	0.000558	0.00461	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—atherosclerosis	0.000551	0.00455	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL6—atherosclerosis	0.000517	0.00427	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ALB—atherosclerosis	0.000494	0.00408	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—atherosclerosis	0.000491	0.00405	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—PPARA—atherosclerosis	0.00049	0.00405	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP7A1—atherosclerosis	0.000489	0.00404	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—APOA1—atherosclerosis	0.00046	0.0038	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—atherosclerosis	0.000452	0.00373	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ALB—atherosclerosis	0.000364	0.00301	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atherosclerosis	0.00034	0.00281	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—atherosclerosis	0.000281	0.00232	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP7A1—atherosclerosis	0.00026	0.00215	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP7A1—atherosclerosis	0.000256	0.00212	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP27A1—atherosclerosis	0.00024	0.00198	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP27A1—atherosclerosis	0.000237	0.00196	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	0.000107	0.000886	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	0.000106	0.000874	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	7.61e-05	0.000628	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PLTP—atherosclerosis	7.15e-05	0.000591	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCG8—atherosclerosis	6.2e-05	0.000512	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LTA4H—atherosclerosis	6.2e-05	0.000512	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCG1—atherosclerosis	4.9e-05	0.000405	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LCAT—atherosclerosis	4.61e-05	0.000381	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—FABP4—atherosclerosis	4.61e-05	0.000381	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APOA4—atherosclerosis	4.52e-05	0.000374	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP7A1—atherosclerosis	4.44e-05	0.000367	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP27A1—atherosclerosis	4.11e-05	0.000339	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALOX15—atherosclerosis	3.89e-05	0.000322	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APOA2—atherosclerosis	3.89e-05	0.000322	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	3.89e-05	0.000322	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	3.89e-05	0.000322	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCG5—atherosclerosis	3.85e-05	0.000318	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LPA—atherosclerosis	3.72e-05	0.000307	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—BGN—atherosclerosis	3.6e-05	0.000297	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APOA5—atherosclerosis	3.56e-05	0.000294	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	3.43e-05	0.000283	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALOX5—atherosclerosis	3.31e-05	0.000273	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NAMPT—atherosclerosis	2.97e-05	0.000245	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LIPC—atherosclerosis	2.95e-05	0.000244	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APOC3—atherosclerosis	2.93e-05	0.000242	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LDLR—atherosclerosis	2.92e-05	0.000241	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CETP—atherosclerosis	2.85e-05	0.000235	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SCARB1—atherosclerosis	2.73e-05	0.000225	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HMGCR—atherosclerosis	2.58e-05	0.000213	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCA1—atherosclerosis	2.3e-05	0.00019	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.97e-05	0.000163	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APOB—atherosclerosis	1.89e-05	0.000156	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.83e-05	0.000152	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LPL—atherosclerosis	1.8e-05	0.000149	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GPX1—atherosclerosis	1.76e-05	0.000145	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CD36—atherosclerosis	1.71e-05	0.000141	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.62e-05	0.000134	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPARA—atherosclerosis	1.59e-05	0.000131	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AGT—atherosclerosis	1.54e-05	0.000127	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APOE—atherosclerosis	1.51e-05	0.000125	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CAV1—atherosclerosis	1.5e-05	0.000124	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APOA1—atherosclerosis	1.49e-05	0.000123	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.36e-05	0.000113	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPARG—atherosclerosis	1.32e-05	0.000109	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—INS—atherosclerosis	1.29e-05	0.000106	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALB—atherosclerosis	1.18e-05	9.76e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NOS3—atherosclerosis	1.13e-05	9.34e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.03e-05	8.54e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AKT1—atherosclerosis	5.2e-06	4.29e-05	CbGpPWpGaD
